Drug Trial Radar · NCT06420440
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Chen XiaopingAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.
Conditions
- HCC
Interventions
Hepatic arterial infusion chemotherapyProcedure
Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
LenvatinibDrug
Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).
TislelizumabDrug
Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)
Liver resectionProcedure
Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.
TislelizumabDrug
Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median event-free survival (EFS)Time frame: From date of randomization until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 60 months.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Shanxi Bethune Hospital
Shanxi, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
Jingmen Central Hospital
Jingmen, Hubei, China · Recruiting
Shiyan Taihe Hospital
Shiyan, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.